Filing Flows

Filing Flows › Companies › Volitionrx › Cash flow

Volitionrx cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.2M in Q2 2026 · −$19.6M over twelve months

Operating cash flow−$5.2M
Capital spending−$2K
Free cash flow−$5.2M

Analysis

In Q2 2026, Volitionrx generated −$5.2M of operating cash flow and spent $2K on capital projects, leaving free cash flow of −$5.2M. That is $1.2M more than in Q2 2025 (−$6.3M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$19.6M; the largest uses were operating cash flow ($19.6M), taxes on employees’ shares ($146K), capital spending ($22K); besides operations, cash came from shares issued ($19.3M), other financing ($685K); the cash balance rose by $535K.

Operating cash flow was −$5.2M against net income of −$7.3M. The largest differences: payables −$1.3M, stock-based pay +$238K, depreciation & amortization +$188K.

Free cash flow

Volitionrx: free cash flow by quarterVolitionrx: free cash flow by quarter−$5.5MQ3 2024−$5.5MQ4 2024−$4.3MQ1 2025−$6.3MQ2 2025−$3.6MQ3 2025−$5.5MQ4 2025−$5.3MQ1 2026−$5.2MQ2 2026
Operating cash flow less capital spending.
Volitionrx: operating cash flow against capital spendingVolitionrx: operating cash flow against capital spendingOperating cash flowCapital spending−$5.4M$137KQ3 2024−$5.4M$73KQ4 2024−$4.3M$2KQ1 2025−$6.3M$77KQ2 2025−$3.6M$0Q3 2025−$5.5M$11KQ4 2025−$5.3M$9KQ1 2026−$5.2M$2KQ2 2026
Latest (Q2 2026): Operating cash flow −$5.2M, Capital spending $2K.

Capital allocation, year by year

Volitionrx: where the cash came from (up) and went (down), by fiscal yearVolitionrx: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY2021: Operating cash flow −$20.9MFY2021: Net borrowing $534KFY2021: Shares issued $23.2MFY2021: Capital spending −$974K$23.8MFY2021FY2022: Operating cash flow −$15.3MFY2022: Shares issued $6.7MFY2022: Capital spending −$1.6M$6.7MFY2022FY2023: Operating cash flow −$18.1MFY2023: Net borrowing $827KFY2023: Shares issued $28.4MFY2023: Capital spending −$1.1MFY2023: Buybacks −$32K$29.2MFY2023FY2024: Operating cash flow −$25.9MFY2024: Net borrowing $281KFY2024: Shares issued $8.6MFY2024: Capital spending −$277K$8.9MFY2024FY2025: Operating cash flow −$19.7MFY2025: Net borrowing $1.1MFY2025: Shares issued $11.2MFY2025: Capital spending −$90K$12.3MFY2025
Over these 5 years operating cash flow totalled −$99.8M; the largest uses were operating cash flow ($99.8M) and capital spending ($4.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$2.8M
Debt$7.1M
Net debt$4.3M
Due within a year$1.6M
Cash runway2 months

Volitionrx is burning cash: its operations consume cash, a free cash flow of −$19.6M a year at the current rate against $2.8M of cash and investments: a runway of about 2 months; $1.6M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Volitionrx: debt maturities by year (FY2025)Volitionrx: debt maturities by year (FY2025)$1.6MYear 1$2.6MYear 2$3.5MYear 3$144KYear 4$144KYear 5$8.0MAfter year 5
Principal due in each year as disclosed in the annual report, against $2.8M of cash and investments now.

Where the cash came from and went

Volitionrx: sources (+) and uses (−) of cash, Q2 2026Volitionrx: sources (+) and uses (−) of cash, Q2 2026Shares issued$5.4MOperating cash flow−$5.2MCash drawn (+) / kept (−)$312KOther financing−$275KNet borrowing (+) / repaid (−)−$180KExchange rates−$129KCapital spending−$2KTaxes on employees’ shares−$125
Volitionrx: sources (+) and uses (−) of cash, TTM to Q2 2026Volitionrx: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$19.6MShares issued$19.3MOther financing$685KCash drawn (+) / kept (−)−$535KNet borrowing (+) / repaid (−)$480KExchange rates−$232KTaxes on employees’ shares−$146KCapital spending−$22K

From profit to cash

Volitionrx: net income to operating cash flow, Q2 2026Volitionrx: net income to operating cash flow, Q2 2026Net income−$7.3MDepreciation & amortization$188KStock-based pay$238KGains on disposals−$341Receivables−$25KPayables−$1.3MDeferred revenue−$176KPrepaid and other assets−$44KOperating cash flow−$5.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$5.2M−$2K−$180K$5.4M$312K−$5.2M
Q1 2026−$5.3M−$9K$717K$5.2M−$2.0M−$5.3M
Q4 2025−$5.5M−$11K$230K$6.7M−$918K−$5.5M
Q3 2025−$3.6M—−$285K$2.0M$2.1M−$3.6M
Q2 2025−$6.3M−$77K−$160K$63K$344K−$6.3M
Q1 2025−$4.3M−$2K$1.3M$2.4M$664K−$4.3M
Q4 2024−$5.4M−$73K$358K$2.0M$2.1M−$5.5M
Q3 2024−$5.4M−$137K−$301K$6.0M$585K−$5.5M

Volitionrx: income statement and cash flow

Volitionrx, Q2 2026: revenue $399K (-2% year over year). The chart follows the revenue to costs, profit and cash.

Volitionrx: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.